Goode, E.A.; Orozco-Moreno, M.; Hodgson, K.; Nabilah, A.; Murali, M.; Peng, Z.; Merx, J.; Rossing, E.; Pijnenborg, J.F.A.; Boltje, T.J.;
et al. Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer Cells. Cancers 2024, 16, 2953.
https://doi.org/10.3390/cancers16172953
AMA Style
Goode EA, Orozco-Moreno M, Hodgson K, Nabilah A, Murali M, Peng Z, Merx J, Rossing E, Pijnenborg JFA, Boltje TJ,
et al. Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer Cells. Cancers. 2024; 16(17):2953.
https://doi.org/10.3390/cancers16172953
Chicago/Turabian Style
Goode, Emily Archer, Margarita Orozco-Moreno, Kirsty Hodgson, Amirah Nabilah, Meera Murali, Ziqian Peng, Jona Merx, Emiel Rossing, Johan F. A. Pijnenborg, Thomas J. Boltje,
and et al. 2024. "Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer Cells" Cancers 16, no. 17: 2953.
https://doi.org/10.3390/cancers16172953
APA Style
Goode, E. A., Orozco-Moreno, M., Hodgson, K., Nabilah, A., Murali, M., Peng, Z., Merx, J., Rossing, E., Pijnenborg, J. F. A., Boltje, T. J., Wang, N., Elliott, D. J., & Munkley, J.
(2024). Sialylation Inhibition Can Partially Revert Acquired Resistance to Enzalutamide in Prostate Cancer Cells. Cancers, 16(17), 2953.
https://doi.org/10.3390/cancers16172953